A double stranded siRNA compound that reduces or inhibits the expression of the TP53 gene, for use in the prevention or reduction of delayed graft function in a kidney transplant recipient, said siRNA compound has the structure: 5 '(N) x - Z 3 '(antisense chain) 3' Z '- (N') and 5 '(sense chain) where each of N and N' is a ribonucleotide that can be modified or unmodified in its sugar residue； wherein each of (N) x and (N ') y is an oligonucleotide in which each consecutive N or N' is linked to the next N or N 'by a covalent bond； where each of x and y is an integer between 18 and 40； wherein each of (N) x and (N ') and the ribonucleotides alternate between modified ribonucleotides and unmodified ribonucleotides, each modified ribonucleotide is a modified ribonucleotide in 2'-O-methyl sugar； wherein each of Z and Z 'may be present or absent, but if present it is 1-5 deoxyribonucleotides covalently linked to the 3' terminal of the oligonucleotide in which it is present； wherein the sequence of (N) x comprises the sequence 5 'UGAAGGGUGAAAUAUUCUC 3' (sec. with identification number: 2) and the sequence of (N ') and comprises the sequence 5' GAGAAUAUUUCACCCUUCA 3 '(section with ID No.:1)； and wherein a therapeutically effective dose of said siRNA compound is for intravenously administered to the kidney transplant recipient between 15 minutes and 4 hours after revascularization of the transplanted kidney, and thereby prevents or reduces the function of graft retardation in the receiver.Un compuesto ARNip bicatenario que reduce o inhibe la expresión del gen TP53, para usar en la prevención o reducción de la función retardada del injerto en un receptor de un trasplante de riñón, dicho compuesto ARNip tiene la estructura: 5' (N)x -Z 3' (cadena antisentido) 3' Z'-(N')y 5' (cadena sentido) en donde cada uno de N y N' es un ribonucleótido que puede ser modificado o no modificado en su residuo azúcar； en donde cada uno de (N)x y (N')y es un oligonucleótido en el cual cada N o N
